Swiss life sciences company Lonza Group ($LONN) is reportedly making a run at Catalent ($CTLT), a U.S.-based pharma services company. Just today, Sweden's Recipharm reported it has completed the first phase of its $205 million (SEK 1.7 billion) two-stage deal for India's Kemwell that expands both its drug development skills and API manufacturing. It has completed the $85 million acquisition of Kemwell's operations in Sweden and Kemwell's Cirrus Pharmaceuticals drug development business in Research Triangle Park, NC.